Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IXP · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Mild Hepatic Impairment | EXPERIMENTAL | Participants will receive a single dose of IXP on Day 1. |
| Cohort 2: Matched Healthy Participants | EXPERIMENTAL | Healthy participants matched to Cohort 1 will receive a single dose of IXP on Day 1. |
| Cohort 3: Moderate Hepatic Impairment | EXPERIMENTAL | Participants will receive a single dose of IXP on Day 1. |
| Cohort 4: Matched Healthy Participants | EXPERIMENTAL | Healthy participants matched to Cohort 3 will receive a single dose of IXP on Day 1. |
| Cohort 1: Severe Renal Impairment | EXPERIMENTAL | Participants will receive a single dose of IXP on Day 1. |
| Cohort 1: Healthy Participants | EXPERIMENTAL | Participants will receive a single dose of IXP on Day 1. |
| Name | Type | Description |
|---|---|---|
| IXP | DRUG | Tablet for oral administration. |
Key Inclusion Criteria: * Cohorts 1 and 3: Participants with Hepatic Impairment * Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A) * Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B) * Cohorts 2 and ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | frexalimab, brivekimig, rilzabrutinib |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Praliciguat |
| Travere Therapeutics, Inc. | TVTX | 1 | PHASE2 | Sparsentan |
| Vera Therapeutics, Inc. Class A | VERA | 1 | PHASE2 | Atacicept |
IXP, also known as inaxaplin, is an investigational small molecule being developed for focal segmental glomerulosclerosis (FSGS) and renal impairment. It is in Phase 1 clinical development by Vertex Pharmaceuticals Incorporated (VRTX).
IXP, also known as inaxaplin, is being developed by Vertex Pharmaceuticals Incorporated, traded on the NASDAQ under the ticker VRTX. The company is conducting Phase 1 clinical trials to evaluate the drug's pharmacokinetics and safety.
IXP, also known as inaxaplin, is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 studies have been completed, one in participants with renal impairment and one in participants with hepatic impairment.
IXP, also known as inaxaplin, has been studied in two completed Phase 1 clinical trials. NCT05865171 evaluated pharmacokinetics and safety in participants with renal impairment, and NCT06529796 evaluated pharmacokinetics and safety in participants with mild or moderate hepatic impairment.
Yes, IXP is the same as inaxaplin. Both names refer to the same investigational small molecule being developed by Vertex Pharmaceuticals Incorporated for focal segmental glomerulosclerosis (FSGS) and renal impairment.